Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway
DOI:
https://doi.org/10.54548/Abstract
Exposure of pesticide and complex I inhibitor, rotenone has been shown to reproduce features of Parkinson's disease, including selective nigrostriatal dopaminergic degeneration and α-synuclein-positive cytoplasmic inclusions. Sixty mice were randomly divided into six groups (n=10) and orally treated for 28 consecutive days as follows; group 1: vehicle (10 mL/kg), group 2- vehicle + rotenone (10 mg/kg p.o. in 0.5% carboxymethyl cellulose (CMC), group 3 – rotenone + 100 mg/kg Luteolin, group 4 – rotenone + 200 mg/kg Luteolin, group 5 - 100 mg/kg Luteolin and group 6 - 200 mg/kg Luteolin, respectively. At the end of the experiment, brain tissues were harvested for biomarkers of oxidative stress, neurobehavioural studies, histology, and immunohistochemistry of Tumour Necrosis Factor alpha (TNF-α), Fragile X Mental Retardation Protein (FXMRP), serotonin, and tyrosine hydroxylase were evaluated. Rotenone toxicity significantly enhanced biomarkers of oxidative stress, acetylcholinesterase activity, and declined antioxidant defense system. Significant reduction in motor coordination and movement disorder together with vacuolation (demyelination) and atrophy of neurons were observed in ROT-untreated mice. Treatment of mice with Luteolin lowered oxidative stress biomarkers, neuroinflammation, Fragile X Mental Retardation Protein expression, improved expression of serotonin and tyrosine hydroxylase production, and restored neuronal ultrastructure anarchy.
Literaturhinweise
Alghamdi AM, Al-Abbasi FA, AlGhamdi SA, Fatima F, Alzarea SI, Kazmi I. (2023). Rosinidin inhibits NF-κB/ Nrf2/caspase-3 expression and restores neurotransmitter levels in rotenone- activated Parkinson's disease. Saudi J Biol Sci. 30(6): 103656. doi: 10.1016/j.sjbs.2023.103656.
Amo-Aparicio J, Daly J, Højen JF, Dinarello CA. (2023). Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease. J Neuroinflammation. 20(1): 147. doi: 10.1186/s12974-023-02830-w. PMID: 37349821; PMCID: PMC10286423.
Armstrong MJ, Okun MS. (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 323(6):548-560. doi: 10.1001/jama.2019.22360. PMID: 32044947.
Azimullah S, Jayaraj RL, Meeran MFN, Jalal FY, Adem A, Ojha S, et al. (2023). Myrcene Salvages Rotenone-Induced Loss of Dopaminergic Neurons by Inhibiting Oxidative Stress, Inflammation, Apoptosis, and Autophagy. Molecules 28(2): 685. doi: 10.3390/molecules28020685. PMID: 36677744; PMCID: PMC9863310.
Azlan UK, Khairul Annuar NA, Mediani A, Aizat WM, Damanhuri HA, Tong X, et al. (2023). An insight into the neuroprotective and anti-neuroinflammatory effects and mechanisms of Moringa oleifera. Front Pharmacol. 13: 1035220. doi: 10.3389/fphar.2022.1035220.
Bai X, Bian Z, Zhang M. (2023). Targeting the Nrf2 signaling pathway using phytochemical ingredients: A novel therapeutic road map to combat neurodegenerative diseases. Phytomed. 109:154582. doi: 10.1016/j.phymed.2022.154582.
Banerjee C, Nandy S, Chakraborty J, Kumar D. (2022). Myricitrin - A flavonoid isolated from the Indian olive tree (Elaeocarpus floribundus) - inhibits Monoamine oxidase in the brain and elevates striatal dopamine levels: Therapeutic implications against Parkinson's disease. Food Funct. 13(12):6545-6559. doi: 10.1039/d2fo00734g. PMID: 35647619.
Bargiotas P, Konitsiotis S. (2013). Levodopa-induced dyskinesias in Parkinson’s disease: Emerging treatments. Neuropsychiatr Dis Treat. 9:1605-1617.
Beal MF. (2002). Oxidatively modified proteins in aging and disease. Free Radic Biol Med. 32(9): 797-803. doi: 10.1016/s0891-5849(02)00780-3. PMID: 11978481.
Behl T, Kaur G, Sehgal A, Zengin G, Singh S, Ahmadi A, et al. (2022). Flavonoids, the family of Plant-Derived Antioxidants Making Inroads into Novel Therapeutic Design Against Ionizing Radiation-Induced Oxidative Stress in Parkinson's Disease. Curr europharmacol. 20(2): 324-343.
Beutler E, Duron O, Kelly MB. (1963). Improved method for determination of blood glutathione reduced. J Lab Clin Med. 61: 882-888.
Bhattacharyya P, Biswas A, Biswas SC. (2023). Brain-enriched miR-128: Reduced in exosomes from Parkinson's patient plasma, improves synaptic integrity, and prevents 6-OHDA mediated neuronal apoptosis. Front Cell Neurosci. 16: 1037903. doi:10.3389/fncel.2022.1037903.
Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, et al. (2019). Randomized phase I clinical trial of anti α-synuclein antibody BIIB054. Mov Disord. 34:1154-1163.
Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ. (2020). Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications. Int J Mol Sci. 21(12): 4391. doi: 10.3390/ijms21124391.
Choi JS, Islam MN, Ali MY, Kim YM, Park HJ, Sohn HS, Jung HA. (2017). The effects of C-glycosylation of luteolin on its antioxidant, anti-Alzheimer's disease, anti-diabetic, and anti-inflammatory activities. Arch Pharm Res. 37(10): 1354-63. doi: 10.1007/s12272- 014-0351-3. Epub 2014 Mar 24. PMID: 24988985.
Chonchaiya W, Schneider A, Hagerman RJ. (2009). Fragile X: a family of disorders. Adv Pediatr. 56: 165-86. doi: 10.1016/j.yapd.2009.08.008.
Christmann A, Gries M, Scholz P, Stahr PL, Law JKY, Schulte S, et al. (2021). The antioxidant rutin counteracts the pathological impact of α-synuclein on the enteric nervous system invitro. Biol Chem. 403(1): 103-122. doi: 10.1515/hsz-2021-0259. PMID:34582634.
Costa C, Tsatsakis A, Mamoulakis C, Teodoro M, Briguglio G, Caruso E, et al. (2017). Current evidence on the effect of dietary polyphenols intake on chronic diseases. Food Chem Toxicol. 110: 286-299. doi: 10.1016/j.fct.2017.10.023.
Daubner SC, Le T, Wang S. (2011). Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 508(1):1-12.
de Rus Jacquet A, Ambaw A, Tambe MA, Ma SY, Timmers M, Grace MH, et al. (2021). Neuroprotective mechanisms of red clover and soy isoflavones in Parkinson's disease models. Food Funct. 12(23): 11987-12007.
DeMaagd G, Philip A. (2015). Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharm Therapeut. 40: 504-532.
Dorsey RE, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Jose C. Adsuar, et al. (2018). Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 17: 939-993.
Drury RA, Wallington EA. (1976). Carlton’s histopathological techniques. 4th ed: 139–142.
Ellman, GL. (1959). Tissue sulfhydryl groups. Arch Biochem Biophys. 82(1): 70-77.
El-Nashar HAS, Abbas H, Zewail M, Noureldin MH, Ali MM, Shamaa MM, et al. (2022). Neuroprotective Effect of Artichoke-Based Nanoformulation in Sporadic Alzheimer's Disease Mouse Model: Focus on Antioxidant, Anti-Inflammatory, and Amyloidogenic Pathways. Pharmaceuticals (Basel) 2022; 15(10): 1202. doi: 10.3390/ph15101202. PMID: 36297313; PMCID: PMC9610800.
Emran TB, Islam F, Nath N, Sutradhar H, Das R, Mitra S, et al. (2022). Naringin and naringenin polyphenols in neurological diseases: Understandings from a therapeutic viewpoint. Life (Basel). 13(1):99. doi: 10.3390/life13010099.
Enogieru AB, Haylett W, Hiss DC, Bardien S, Ekpo OE. (2018). Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders. Oxid Med Cell Longev. 2018: 6241017. doi: 10.1155/2018/6241017. PMID: 30050657; PMCID: PMC6040293.
Essam RM, Kandil EA. (2023). p-CREB and p-DARPP-32 orchestrating the modulatory role of cAMP/PKA signaling pathway enhanced by Roflumilast in rotenone-induced Parkinson's disease in rats. Chem Biol Interact. 372: 110366. doi: 10.1016/j.cbi.2023.110366. Epub ahead of print. PMID: 36706892.
Fahn S. (2018). The 200-year journey of Parkinson disease: reflecting on the past and looking towards the future. Parkinsonism Relat Disord. 46: S1–S5.
Fedorova M, Bollineni RC, Hoffmann R. (2014). Protein carbonylation as a major hallmark of oxidative damage: update of analytical strategies. Mass Spectrom Rev. 33(2): 79-97. doi: 10.1002/mas.21381. Epub 2013 Jul 7. PMID: 23832618.
Fleiss JL, Levin B, Paik MC. (2003). Statistical Methods for Rates and Proportions, Third Edition, John Wiley & Sons, New York.
Gallardo-Fernández M, Hornedo-Ortega R, Cerezo AB, Troncoso AM, Garcia-Parrilla MC. (2023). Hydroxytyrosol and dopamine metabolites: Anti-aggregative effect and neuroprotective activity against α-synuclein-induced toxicity. Food Chem Toxicol. 171: 113542. doi:10.1016/j.fct.2022.113542.
Gornal AG, Bardawill JC, David MM. (1949). Determination of serum proteins by means of Biuret reaction. J Biol Chem. 177: 751-766
Habig WH, Pabst MJ, Jakpoby WB. (1974). Glutathione S-transferase, a first enzymatic step in mercapturic acid formation. J Biol Chem. 249: 7130-7139
Hall D, Pickler L, Riley K, Tassone F, Hagerman R. (2010). Parkinsonism and cognitive decline in a fragile X mosaic male. Mov Disord. 25(10): 1523-4. doi: 10.1002/mds.23150. PMID: 20568092; PMCID: PMC4051493.
Idriss HT, Naismith JH. (2000). TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 50(3): 184-195.
Ishola IO, Awogbindin IO, Olubodun-Obadun TG, Olajiga AE, Adeyemi OO. (2023). Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symptoms through attenuation of oxidative stress, neuroinflammation and α-synuclein expressions in rats. Neurotoxicol. 96:37-52.
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, et al. (2018). Safety and tolerability of multiple ascending doses of PRX002/RG7935, an Anti α-Synuclein monoclonal antibody, in patients with Parkinson disease. JAMA Neurol. 75:1206-1214.
Jankovic J. (2019). Pathogenesis-targeted therapeutic strategies in Parkinson’s disease. Mov Disord. 34:41-44.
Jing L, Hou L, Zhang D, Li S, Ruan Z, Zhang X, Hong JS, Wang Q. (2021). Microglial Activation Mediates Noradrenergic Locus Coeruleus Neurodegeneration via Complement Receptor 3 in a Rotenone-Induced Parkinson's Disease Mouse Model. J Inflamm Res. 14: 1341-1356. doi: 10.2147/JIR.S299927. PMID: 33859489; PMCID: PMC8044341.
Jung UJ, Kim SR. (2018). Beneficial effects of flavonoids against Parkinson's disease. J Med Food. 21(5): 421-432. doi: 10.1089/jmf.2017.4078.
Kartik S, Pal R, Chaudhary MJ, Nath R, Kumar M, Binwal M, Bawankule DU. (2023). Neuroprotective role of chloroquine via modulation of autophagy and neuroinflammation in MPTP-induced Parkinson's disease. Inflammopharmacology. 31(2): 927-941. doi: 10.1007/s10787-023-01141-z.
Kim HN, Pak ME, Shin MJ, Kim SY, Shin YB, Yun YJ, Shin, HK, et al. Comparative analysis of the beneficial effects of treadmill training and lector acupuncture in a rat model of neonatal hypoxia-ischemia. Int J Mol Med. 3 9(6): 1393-1402.
Korczyn AD. (2004). Drug treatment of Parkinson's disease. Dialogues Clin Neurosci. 6(3):315-22. doi: 10.31887/DCNS.2004.6.3/akorczyn.
Korovesis D, Rubio-Tomás T, Tavernarakis N. (2023). Oxidative Stress in Age-Related neurodegenerative diseases: An overview of recent tools and findings. Antioxidants (Basel). 12(1): 131. doi: 10.3390/antiox12010131. PMID: 36670993; PMCID: PMC9854433.
Koszła O, Stępnicki P, Zięba A, Grudzińska A, Matosiuk D, Kaczor AA. (2021). Current Approaches and Tools Used in Drug Development against Parkinson's Disease. Biomolecules. 11(6):897. doi: 10.3390/biom11060897.
Kothawade SM, Buttar HS, Tuli HS, Kaur G. (2023). Therapeutic potential of flavonoids in the management of obesity-induced Alzheimer's disease: an overview of preclinical and clinical studies. Naunyn Schmiedebergs Arch Pharmacol. 396(11):2813-2830. doi: 10.1007/s00210-023-02529-y.
Kulkarni A, Preeti K, Tryphena KP, Srivastava S, Singh SB, Khatri DK. (2023). Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics. Ageing Res Rev. 84:101816.
Kumar V, Bishayee K, Park S, Lee U, Kim J. (2023). Oxidative stress in cerebrovascular disease and associated diseases. Front Endocrinol (Lausanne). 14: 1124419. doi: 10.3389/fendo.2023.1124419. PMID: 36875474; PMCID: PMC9982100.
Li L, Luo W, Qian Y, Zhu W, Qian J, Li J, et al. (2019). Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses. Phytomed. 59: 152774. doi: 10.1016/j.phymed.2018.11.034. Epub 2018 Nov 28. PMID: 31009852.
Li L, Zhou R, Lv H, Song L, Xue X, Wu L. (2021). Inhibitive Effect of Luteolin on Sevoflurane-Induced Neurotoxicity through Activation of the Autophagy Pathway by HMOX1. ACS Chem Neurosci. 12(18): 3314-3322.
Lü MH, Wang ZP, Xing LZ, Zhang W, Han F, Huang GL, et al. (2023). Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for Parkinson’s disease: Disaggregate α-Synuclein fibrils inhibit inclusions and repair damaged neurons in mice. Eur J Med Chem. 249:115122. doi: 10.1016/j.ejmech.2023.115122.
MacFarlane M. (2003). TRAIL-induced signalling and apoptosis. Toxicol Lett. 139(2-3): 89-97. doi: 10.1016/s0378-4274(02)00422-8. PMID: 12628743.
Mani S, Bouchnak H, Pradeloux S, Kraiem J, Soulet D, Messaoudi I. (2023). 3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease. Clin Exp Pharmacol Physiol. 50(9):728-737. doi: 10.1111/1440-1681.13799. Epub 2023 Jun 18.
Marino BLB, de Souza LR, Sousa KPA, Ferreira JV, Padilha EC, da Silva CHTP, et al. (2020). Parkinson's Disease: A Review from Pathophysiology to Treatment. Mini Rev Med Chem. 20(9):754-767.
Mhalhel K, Sicari M, Pansera L, Chen J, Levanti M, Diotel N, et al. (2023). Zebrafish: A model deciphering the impact of flavonoids on neurodegenerative disorders. Cells.12(2):252. doi: 10.3390/cells12020252.
Misra HP, Fridovich I. (1972). The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 217: 3170-3175.
Musheghyan G, Arajyan G, Poghosyan M, Hovsepyan V, Sarkissian J. (2023). Synaptic processes in the antinociceptive somatosensory cortex of the brain activated by the ventral posterior-lateral thalamic nucleus in a rotenone model of Parkinson’s disease. Georgian Med News. Mar:(336):117-122.
Nabavi SF, Braidy N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Woźniak K, et al. (2015). Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Res Bull. 119(Pt A): 1-11. doi: 10.1016/j.brainresbull.2015.09.002.
Nagatsu T, Nakashima A, Watanabe H, Ito S, Wakamatsu K, Zucca FA, et al. (2023). The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease. J Neural Transm (Vienna). 130(5): 611-625.
Neal ML, Beier EE, Hossain MM, Boyle A, Zheng J, Kim C, et al. (2023). Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson's Disease Models. Antioxidants (Basel). 12(3): 582. doi: 10.3390/antiox12030582. PMID: 36978830; PMCID: PMC10044828.
Olaleye SB, Adaramoye OA, Erigbali PP, Adeniyi OS. (2007). Lead exposure increases oxidative stress in gastric mucosa of HCL/ethanol exposed rat. World J Gastreoenterol. 13:5121-5126
Olufunmilayo EO, Gerke-Duncan MB, Holsinger RMD. (2023). Oxidative Stress and Antioxidants in Neurodegenerative Disorders. Antioxidants (Basel). 12(2): 517. doi: 10.3390/antiox12020517. PMID: 36830075; PMCID: PMC9952099.
Onukak CE, Femi-Akinlosotu OM, Obasa AA, Folarin OR, Ajibade TO, Igado OO, Esan OO, Oyagbemi, TO, Adeogun AV, Oyagbemi AA, Ola-Davies OE, Omobowale TO, Olopade JO, Oguntibeju OO, Yakubu MA. (2025). Epigallocatechin -3- gallate mitigates diazinon neurotoxicity via suppression of pro-inflammatory genes and upregulation of antioxidant pathways. BMC Neuroscience. 26:22. https://doi.org/10.1186/s12868-025-00943-x.
Oyagbemi AA, Adebayo AK, Adebiyi OE, Adigun KO, Folarin OR, Esan OO, et al. (2023). Leaf extract of Anacardium occidentale ameliorates biomarkers of neuroinflammation, memory loss, and neurobehavioral deficit in N(ω)-nitro-L-arginine methyl ester (L-NAME) treated rats. Biomarkers. 28(3): 263-272. doi: 10.1080/1354750X.2022.2164354.
Oyagbemi AA, Omobowale TO, Awoyomi OV, Ajibade TO, Falayi OO, Ogunpolu BS, et al. (2019). Cobalt chloride toxicity elicited hypertension and cardiac complication via induction of oxidative stress and upregulation of COX-2/Bax signaling pathway. Hum Exp Toxicol. 38(5): 519-532
Panchal SK, Brown L. (2022). Potential Benefits of Anthocyanins in Chronic Disorders of the central nervous system. Molecules. 28(1): 80. doi: 10.3390/molecules28010080.
Patel A, Rasheed A, Reilly I, Pareek Z, Hansen M, Haque Z, et al. (2022). Modulation of Cytoskeleton, Protein Trafficking, and Signaling Pathways by Metabolites from Cucurbitaceae, Ericaceae, and Rosaceae Plant Families. Pharmaceuticals (Basel). 15(11):1380.
Rahimpour P, Nasehi M, Zarrindast MR, Khalifeh S. (2023). Dose-dependent manner of luteolin in the modulation of spatial memory with respect to the hippocampal level of HSP70 and HSP90 in sleep-deprived rats. Gene. 852: 147046. doi: 10.1016/j.gene.2022.147046.
Rajendran P, Althumairy D, Bani-Ismail M, Bekhet GM, Ahmed EA. (2023). Isoimperatorin therapeutic effect against aluminum induced neurotoxicity in albino mice. Front Pharmacol. 14: 1103940.
Reyes ZMD, Lynch E, Henry J, De Simone LM, Sobotka SA. (2023). Diagnosis of autism in a rare case of tyrosine hydroxylase deficiency: A case report. BMC Med Genomics 2023; 16(1): 78. doi:10.1186/s12920-023-01510-1. PMID: 37041529; PMCID:PMC10088295.
Reznick AZ, Packer L. (1994). Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 233: 357-363. doi: 10.1016/s0076-6879(94)33041-7. PMID: 8015470.
Rodrigues-Costa M, Fernandes MSS, Jurema-Santos GC, Gonçalves LVDP, Andrade-da Costa BLDS. (2023). Nutrigenomics in Parkinson's disease: diversity of modulatory actions of polyphenols on epigenetic effects induced by toxins. Nutr Neurosci. 26(1): 72-84.
Rodríguez-Arce E, Saldías M. (2021). Antioxidant properties of flavonoid metal complexes and their potential inclusion in the development of novel strategies for the treatment against neurodegenerative diseases. Biomed Pharmacother. 143: 112236. doi: 10.1016/j.biopha.2021.112236. Epub 2021 Sep 30. PMID: 34649360.
Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T. (2010). Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull. 82(5-6): 279-83. doi:10.1016/j.brainresbull.2010.06.004. Epub 2010 Jun 15. PMID: 20558255.
Romagnoli A, Di Marino D. (2021). The Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities. Front Psychiatry. 12: 754485. doi: 10.3389/fpsyt.2021.754485. PMID: 34803767; PMCID: PMC8599826.
Roy Z, Bansal R, Siddiqui L, Chaudhary N. (2023). Understanding the Role of Free Radicals and Antioxidant Enzymes in Human Diseases. Curr Pharm Biotechnol. 24(10): 1265-1276.
Santulli C, Bon C, De Cecco E, Codrich M, Narkiewicz J, Parisse P, Perissinotto F, Santoro C, Persichetti F, Legname G, Espinoza S, Gustincich S. (2022). Neuronal haemoglobin induces loss of dopaminergic neurons in mouse Substantia nigra, cognitive deficits and cleavage of endogenous α-synuclein. Cell Death Dis. 13(12): 1048. doi:10.1038/s41419-022-05489-y. PMID: 36526614; PMCID: PMC9758156.
Scanga A, Lafontaine AL, Kaminska M. (2023)). An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson's disease. J Clin Sleep Med. 19(6):1133-1144. doi: 10.5664/jcsm.10450.
Sergi CM. (2022). Epigallocatechin gallate for Parkinson's disease. Clin Exp Pharmacol Physiol. 49(10): 1029-1041. doi: 10.1111/1440-1681.13691.
Sharma A, Weber D, Raupbach J, Dakal TC, Fließbach K, Ramirez A, et al. (2020). Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease. Redox Biol. 34: 101546. doi: 10.1016/j.redox.2020.101546. Epub 2020 May 18. PMID: 32460130; PMCID: PMC7251371.
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. (2003). Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 23(34): 10756-64. doi:10.1523/JNEUROSCI.23-34-10756.2003. PMID: 14645467; PMCID: PMC6740985.
Simon DK, Tanner CM, Brundin P. (2020). Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr. 36: 1-12.
Singh R, Zahra W, Singh SS, Birla H, Rathore AS, Keshri PK et al. (2023). Oleuropein confers neuroprotection against rotenone-induced model of Parkinson's disease via BDNF/CREB/Akt pathway. Sci Rep. 13(1):2452. doi: 10.1038/s41
Song MY, Lee DY, Chun KS, Kim EH. (2021). The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism. Int J Mol Sci. 22(9): 4376. doi: 10.3390/ijms22094376. PMID: 33922165; PMCID: PMC8122702.
Spohr L, de Aguiar MSS, Bona NP, Luduvico KP, Alves AG, Domingues WB, et al. (2022). Blueberry extract modulates brain enzymes activities and reduces neuroinflammation: Promising effect on lipopolysaccharide-induced depressive-like behavior. Neurochem Res. 48(3):846-861. doi: 10.1007/s11064-022-03813-8.
Tan Y, Sgobio C, Arzberger T, Machleid F, Tang Q, Findeis E, et al. (2020). Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease. Acta Neuropathol. 139(2): 319-345. doi: 10.1007/s00401-019-02099-5. Epub 2019 Nov 25. PMID: 31768670.
Tanase M, Urbanska AM, Zolla V, Clement CC, Huang L, Morozova K, et al. (2016). Role of Carbonyl Modifications on Aging-Associated Protein Aggregation. Sci Rep. 6: 19311. doi: 10.1038/srep19311. PMID: 26776680; PMCID: PMC4726109.
Tsarouchi M, Fanarioti E, Karathanos VT, Dermon CR. (2022). Protective effects of currants (Vitis vinifera) on corticolimbic serotoninergic alterations and anxiety-like comorbidity in a rat Model of Parkinson's Disease. Int J Mol Sci. 24(1): 462. doi: 10.3390/ijms24010462.
Ursu MGS, Milea ȘA, Păcularu-Burada B, Dumitrașcu L, Râpeanu G, Stanciu S, et al. (2022). Optimizing of the extraction conditions for anthocyanin's from purple corn flour (Zea mays L): Evidences on selected properties of optimized extract. Food Chem Toxcol 2022; 17: 100521. doi: 10.1016/j.fochx.2022.100521. PMID: 36471760; PMCID: PMC9718927.
Varshney R, Kale RK. (1990). Effect of calmodulin antagonists on radiation induced lipid peroxidation in microsomes. Int J Radiat Biol. 58: 733-743.
Vastegani SM, Khoshnam SE, Mansouri E, Ghafouri S, Bakhtiari N, Farbood Y, et al. (2023). Anti-inflammatory, anti-apoptotic, and neuroprotective potentials of anethole in Parkinson's disease-like motor and non-motor symptoms induced by rotenone in rats. Metab Brain Dis. 38(6):2159-2174. doi: 10.1007/s11011-023-01230-6.
von Wrangel C, Schwabe K, John N, Krauss JK, Alam M. (2015). The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings. Behav Brain Res. 279: 52-61. doi: 10.1016/j.bbr.2014.11.002.
Wang L, Zhang X, Xiong X, Zhu H, Chen R, Zhang S, et al. (2022). Nrf2 Regulates Oxidative Stress and Its Role in Cerebral Ischemic Stroke. Antioxidants (Basel). 11(12): 2377. doi: 10.3390/antiox11122377.
Wang S, El-Deiry WS. (2023). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 22(53):8628-8633. doi: 10.1038/sj.onc.1207232. PMID: 14634624.
Wang Y, Wu S, Li Q, Lang W, Li W, Jiang X, et al. (2022). Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease. Front Pharmacol. 13:977521. doi: 10.3389/fphar.2022.977521.
Wang Z, Yang D, Jiang Y, Wang Y, Niu M, Wang C, et al. (2023). Loss of RAB39B does not alter MPTP-induced Parkinson's disease-like phenotypes in mice. Front Aging Neurosci. 15:1087823. doi: 10.3389/fnagi.2023.1087823. PMID: 36761179; PMCID: MC9905435.
Wolff SF. (1994). Ferrous ion oxidation in the presence of ferric ion indicator xylenol orange for measurement of hydrogen peroxides. Methods Enzymol. 233: 182-189.
Xia Y, Zweiler JL. (1997). Measurement of myeloperoxidase in leucocyte containing tissue. Anal Biochem. 245: 93-96
Xu Y, Meng X, Zhao WX, Liu DG, Zhu JG, Yao R, et al. (2023). Neuroprotective effect of ginsenoside Re on drosophila model of Parkinson's disease. Zhongguo Zhong Yao Za Zhi. 48(7): 1927-1935.
Yamamoto H, Matsumura R, Nakashima M, Adachi M, Ogawa K, Hongo K, et al. (2023). Effects of the polyphenols delphinidin and rosmarinic acid on the inducible intra-cellular aggregation of alpha-Synuclein in model neuron cells. Appl Biochem Biotechnol. 195(7):4134-4147. doi: 10.1007/s12010-023-04362-8.
Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, Ren SM, et al. (2010). Treatment strategies for Parkinson's disease. Neurosci Bull. 26(1): 66-76.
Zahra W, Rai SN, Birla H, Singh SS, Rathore AS, Dilnashin H, Singh R, Keswani C, Singh RK, Singh SP. (2020). Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model. CNS Neurol Disord Drug Targets. 19(7): 527-540.
Zhang X, Zhang K, Wang Y, Ma R. (2020). Effects of Myricitrin and Relevant Molecular Mechanisms. Curr Stem Cell Res Ther. 15(1): 11-17. doi: 10.2174/1574888X14666181126103338. PMID: 30474534.
Zhu Q, Meng P, Han Y, Yang H, Yang Q, Liu Z, et al. (2022). Luteolin Induced Hippocampal Neuronal Pyroptosis Inhibition by Regulation of miR-124-3p/TNF-α/TRAF6 Axis in Mice Affected by Breast-Cancer-Related Depression. Evid Based Complement Alternat Med. 2022 May 6:2022:2715325. doi: 10.1155/2022/2715325. eCollection 2022.
Veröffentlicht
Ausgabe
Rubrik
Lizenz
Copyright (c) 2025 Nigerian Journal of Physiological Sciences
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung 4.0 International.
